Originator list for PBS medicines on F2 formulary - stakeholder consultation - brand of octreotide added
Page last updated: 12 August 2015
The National Health Act 1953 has recently been amended to implement measures announced as part of the PBS Access and Sustainability package. This includes removing the originator brand from price disclosure calculations.
More information on the amendments to the Act and explanatory material can be found on the Parliament of Australia website.
A table of PBS drugs on the F2 formulary and brands which it is proposed may be determined as originator brands (under subsection 99ADB(6B) of the Act) is included below. The table has been updated to reflect 1 August 2015 changes to include propranolol and remove a brand of desferrioxamine. Several additional Diabex brands and the Sandostatin 0.5 brand omitted in error from the previous version have been included. These changes are not in response to comments received from stakeholders.
- Originator list for PBS medicines on F2 formulary – stakeholder consultation – updated list 11 August 2015 (Word 60KB )
- Originator list for PBS medicines on F2 formulary – stakeholder consultation – updated list 11 August 2015 (PDF 1187KB )
Amendments to the National Health (Pharmaceutical Benefits) Regulations 1960 will provide further details regarding the circumstances in, and the method by which, an originator brand would be removed from price disclosure calculations. Originator brand data will still need to be submitted for each cycle as it will always be used for some parts of the calculations. A Fact Sheet about originator removal and changes to the calculation method is now available at Fact Sheet – 2015 Price Disclosure Changes
Written feedback and comments on the proposed originator brands can be provided to the Department of Health via email to Legislation&IndustryPolicy@health.gov.au
The closing date for comments has been extended to 14 August 2015.
